Development and Validation of a HPLC and an UV Spectrophotometric Methods for Determination of Dexibuprofen in Pharmaceutical Preparations by Muralidharan, Selvadurai & Meyyanathan, Subramania Nainar
International Scholarly Research Network
ISRN Pharmaceutics
Volume 2011, Article ID 948314, 4 pages
doi:10.5402/2011/948314
Research Article
Developmentand Validation of a HPLC and an UV
SpectrophotometricMethods forDeterminationof
Dexibuprofen in Pharmaceutical Preparations
SelvaduraiMuralidharanandSubramaniaNainarMeyyanathan
Department of Pharmaceutical Analysis, JSS College of Pharmacy, Ootacamund, Tamilnadu-643 001, India
Correspondence should be addressed to Selvadurai Muralidharan, muraliaimst@gmail.com
Received 12 April 2011; Accepted 16 May 2011
Academic Editors: G. N. C. Chiu and F. de la Calle
Copyright © 2011 S. Muralidharan and S. N. Meyyanathan.ThisisanopenaccessarticledistributedundertheCreativeCommons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
A high-performance liquid chromatographic (HPLC) and a ultraviolet (UV) methods were developed and validated for the
quantitative determination of Dexibuprofen (DI) in pharmaceutical dosage form. HPLC was carried out by reversed phase
technique on a RP-18 column with a mobile phase composed of acetonitrile and 0.5% triethylamine (pH 7.5 adjusted with
orthophosphoric acid (30:70, v/v)). UV method was performed with the λ max at 222.0nm. Both the methods showed good
linearity, reproducibility and precision. No spectral or chromatographic interferences from the tablet excipients were found in
UV and HPLC. The method was successfully applied to commercial DEXIFEN tablets. Validation parameters such as linearity,
precision, accuracy, and speciﬁcity were determined. The proposed method could be applicable for routine analysis of DI and
monitoring of the quality of marketed drugs.
1.Introduction
Nonsteroidal anti-inﬂammatory drugs (NSAIDs) like ± ibu-
profenareeﬀectiveforthereliefofpain,andtheiruseiswide-
spread [1–3]. ± ibuprofen, which contains equal quantities
of (+) Ibuprofen and (−) Ibuprofen, has been used as an
anti-inﬂammatory and analgesic agent for over 30 years.
(+) Ibuprofen, or Dexibuprofen, is the pharmacologically
eﬀective enantiomer of + ibuprofen [1–3]. The present UV
and HPLC methods are relatively simple, rapid, and highly
sensitive in the determination of dexibuprofen.
Only limited methods have been reported in the liter-
ature survey [4–10]. The aim of the present work was to
develop and validate a simple, fast, and reliable isocratic RP-
HPLC and UV method for the determination of DI in phar-
maceuticaldosageforms.Theimportantfeaturesandnovelty
of the proposed method included simple sample treatment
with sonication of small amount of powder sample at ambi-
ent temperature, centrifugation, and dilution; short elution
time with internal standard eluted prior to DI; good preci-
sion (R.S.D. less than 5%) and high recovery (greater than
95%). Conﬁrmation of the applicability of the developed
method was validated according to the International Con-
ference on Harmonisation (ICH), to determination of DI in
pharmaceutical dosage forms.
2. Experimental
2.1. Chemicals. HPLC grade acetonitrile (ACN) and trieth-
ylamine (A.R. grade) were purchased from Qualigens Fine
Chemicals, Mumbai. Water HPLC grade was obtained
from a Milli-QRO water puriﬁcation system. Dexibuprofen
standardandibuprofen(Internalstandard)wereprovidedby
Noven Life Sciences Private Limited, Hyderabad, India.
2.2. Instrumentation and Analytical Conditions. HPLC chro-
matographic separation was performed on a Shimadzu liq-
uid chromatographic system equipped with a LC-10AT-
vp solvent delivery system (pump), SPD M-10AVP photo
diode array detector, and Rheodyne 7725i injector with
50μL loop volume. Class-VP 6.01 data station was applied2 ISRN Pharmaceutics
for data collecting and processing (Shimadzu, Japan). The
HPLC was carried out at a ﬂow rate of 1.0mLmin−1 using
a mobile that is phase constituted of acetonitrile—50mM
potassium dihydrogen orthophosphate (pH 7.5 adjusted
with orthophosphoric acid (45:55,v/v)), and detection was
made at 222.0nm. The mobile phase was prepared daily,
ﬁltered through a 0.45μm membrane ﬁlter (Millipore) and
sonicatedbeforeuse.APrincetonSPHERC18 column (25cm
× 4.6mm i.d., 5μ) was used for the separation. UV method
was performed on a UV-VISIBLE spectrophotometer, UV-
160 (Shimadzu) with the λ at 222.0nm and using 1.0cm
quartz cell.
2.3. Preparation of Standard Solutions
2.3.1. HPLC Method. For the calibration curve, accurately
weighed 100.0mg of DI was transferred to a 100mL volu-
metric ﬂask and dissolved in a mixture of water and meth-
anol of the ratio 1:1v/v. From this solution, other solutions
with concentrations of 10.0, 20.0, 30.0, 40.0, 50.0, and
60.0μgmL −1 were obtained by diluting adequate amounts in
triplicate.
2.3.2. UV Method. For the calibration curve, accurately
weighed 100.0mg of DI was transferred to a 100mL
volumetric ﬂask and dissolved in a mixture of water and
methanol of the ratio 1:1v/v. From this solution, other
solutions with concentrations of 2.0, 4.0, 6.0, 8.0, 10.0, and
12.0μgmL −1 were obtained by diluting adequate amounts in
triplicate.
2.4. Preparation of Sample Solutions
2.4.1. HPLC Method. Twenty tablets, each containing 200.0,
300.0,and400.0mgofDIwereweighedandﬁnelypowdered;
a quantity of powder equivalent to 20.0, 30.0 and 40.0mg of
DI was weighed and transferred to a sintered glass crucible.
Tothis5.0mLof1.0mgmL−1 solutionofibuprofenwasadd-
edandthedrugswereextractedwiththreequantities,eachof
20mLofmixtureofmethanolandwater(1:1v/v).Thecom-
bined extracts were made up to 100mL with mobile phase,
and further dilutions were made to get a concentration of
20.0, 30.0, and 40.0μg/mL of dexibuprofen, 50.0μg/mL of
Ibuprofen as internal standard, and this solution was used
for the estimation.
2.4.2. UV Method. A c c u r a t e l yw e i g h e da m o u n to fp o w d e r
equivalent to 20.0, 30.0, and 40.0mg of DI was transferred
to 100mL volumetric ﬂask and dissolved in the mobile phase
to obtain a concentration of 20.0, 30.0, and 40.0μgmL −1.A n
aliquot of this solution was diluted in mobile phase to obtain
a solution with ﬁnal concentration of 4.0μgmL −1.
2.5. Method Validation. The objective of method validation
is to demonstrate that the method is suitable for its intended
purpose as it is stated in ICH guidelines [11]. The method
was validated for linearity, precision (repeatability and inter-
mediate precision), accuracy speciﬁcity, short-term stability,
and system suitability. Standard plots were constructed with
six concentrations in the range of 10–60μgmL −1 prepared
in triplicates to test linearity. The ratio of peak area signal
of DI to that of IS was plotted against the corresponding
concentration to obtain the calibration graph. The linearity
wasevaluatedbylinearregressionanalysisthatwascalculated
by the least square regression method. The precision of the
assay was studied with respect to both repeatability and in-
termediate precision. Repeatability was calculated from
six replicate injections of freshly prepared DI solution in
the same equipment at a concentration 50μgmL −1 of the
intended test concentration value on the same day. The
experiment was repeated by assaying freshly prepared solu-
tion at the same concentration additionally on two consecu-
tive days to determine intermediate precision. Peakarea ratio
ofDItothatofISwasdeterminedandprecisionwasreported
as % R.S.D. Method accuracy was tested (% recovery and
% R.S.D. of individual measurements) by analysing samples
of DI at three diﬀerent levels in pure solutions using three
preparations for each level. The results were expressed as the
percentage of DI recovered in the samples. Speciﬁcity was
assessed by comparing the chromatograms obtained from
sample of pharmaceutical preparation and standard solution
with those obtained from excipients which take part in the
commercialtabletsandverifyingtheabsenceofinterferences.
Sample solution short-term stability was tested at ambient
temperature (20 ± 1◦C) for three days. In order to conﬁrm
the stability of both standard solutions at 100% level and
tablets sample solutions, both solutions protected from light
were reinjected after 24 and 48h at ambient temperature
and compared with freshly prepared solutions. A system
suitabilitytestwasperformedbysixreplicateinjectionsofthe
standard solution at a concentration of 50μgmL −1 verifying
IS/DIresolution>2,%R.S.D.ofpeakarearatiosofDItothat
of IS ±2%, % R.S.D. of each peak retention time ±2%.
3. Results and Discussion
3.1. Validation of Methods
3.1.1. Linearity. Six point calibration graphs were construct-
ed covering a concentration range of 10–60mgmL−1.T h r e e
independentdeterminationswereperformedateachconcen-
tration. Linear relationships between the ratio of the peak
area signal of DI to that of IS versus the corresponding
drug concentration were observed, as shown by the results
presented in Table 1. The standard deviations of the slope
and intercept were low. The determination coeﬃcient (r2)
exceeded 0.99 (Figure 2).
3.1.2. Precision. The carried out repeatability study (n = 6)
showed a R.S.D. of 0.858% for the peak area ratios of DI to
that of IS obtained, thus showing that the equipment used
for the study worked correctly for the developed analytical
method and is highly repetitive. For the intermediate pre-
cision, a study carried out by the same analyst working onISRN Pharmaceutics 3
Table 1: Results of regression analysis of data for the quantitative determination of dexibuprofen by the proposed methods.
Statistical parameters HPLC UV
Concentration range (μgmL −1) 10–60 2–12
Regression equation y = 0.0186x +0 .044 y = 0.1117 +0.0095
Correlation coeﬃcient (r) 0.9915 0.9973
Table 2: Accuracy study for Dexibuprofen (n = 5).
Nominal concentration μgmL −1 (HPLC) Nominal concentration μgmL −1 (UV) Mean recovery (%) R.S.D. (%)
HPLC UV HPLC UV
10.00 2.0 8.30 1.91 0.32 0.12
30.00 6.0 28.24 6.05 0.78 0.35
60.00 12.0 57.99 11.68 1.02 0.62
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Figure 1: Typical sample chromatogram of dexibuprofen and
internal standard.
Table 3: System suitability study (HPLC).
Retention time (min) DI (50μg/mL) IS (10μg/mL)
Mean (n = 5) 7.53 11.12
% R.S.D. 0.39 0.13
two consecutive days (n = 3) indicated a R.S.D. of 0.744%.
Both values were far below 5%, the limit percentage set for
the precision, and indicated a good method precision.
3.1.3. Accuracy. The data for accuracy were expressed in
terms of percentage recoveries of DI in the real samples.
These results are summarized in Table 2.T h em e a nr e c o v e r y
data of DI in real sample were within the range of 100.01
and 102.28%, and mean % R.S.D. was 1.04%, satisfying the
acceptance criteria for the study.
3.1.4. Speciﬁcity. The HPLC chromatogram recorded for the
mixture of the drug excipients revealed no peak within a re-
y = 0.0092x −0.0003
R2 = 0.9998
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Figure 2: Calibration curve of dexibuprofen.
tention time range of 5min. The results showed that the de-
veloped method was speciﬁc as none of the excipients inter-
fered with the analytes of interest (Figure 1).
3.1.5. Stability. The stability of DI in standard and sample
solutions containing IS was determined by storing the solu-
tions at ambient temperature (20 ± 1◦C) protected from
light. The solutions were checked in triplicate after three
successive days of storage, and the data were compared with
freshly prepared samples. In each case, it could be noticed
that solutions were stable for 72h, as during this time the
results did not decrease below 97%. This denotes that DI is
stable in standard and sample solutions for at least 3 days
at ambient temperature, protected from light, and is com-
patible with IS.
3.1.6. System Suitability. The resolution factor between IS
and DI, in the developed method, was above 2. The % R.S.D.
of peak area ratio of DI to that of IS and retention times for
both drug and IS were within 2% indicating the suitability of
the system (Table 3). These results indicate the applicability4 ISRN Pharmaceutics
Table 4: Results obtained for determination of dexibuprofen in SIBET marketed formulations.
HPLC UV HPLC UV
Drug Amount mg/tab Amount mg/tab % Recovery
Labelled Found Labelled Found
400 385.23 400 378.89 96.30 95.89
Dexibuprofen 300 291.98 300 285.67 97.32 93.12
200 189.83 200 185.42 94.91 92.05
of this method to routine with no problems, with its suit-
ability being proved. The statistical evaluation of the pro-
posed method revealed its good linearity, reproducibility,
and its validation for diﬀerent parameters and led us to the
conclusion that it could be used for the rapid and reliable
determination of DI in pharmaceutical forms.
3.1.7. Assay of Tablets. The validated method was applied for
the assay of commercial tablets containing 200mg, 300mg,
and 400mg of DI (DEXIFEN); each sample was analysed in
triplicate after extracting the drug as mentioned in the assay
sample preparation of Section 2 and injections were carried
out in triplicate. Figure 1 shows an HPLC chromatogram of
DI in pharmaceutical tablets. None of the tablets ingredients
interfered with the analyte peak. The results presented in
Table 4 are in good agreement with the labelled content.
4. Conclusion
A validated isocratic HPLC and UV methods has been
developed for the determination of DI in dosage forms. The
proposed method issimple, rapid, accurate,precise,and spe-
ciﬁc. Its chromatographic run time of 10.5min allows the
analysis of a large number of samples in a short period of
time. Therefore, it is suitable for the routine analysis of DI in
pharmaceutical dosage forms. The simplicity of the method
allows for application in laboratories that lack sophisticated
analytical instruments such as LC-MS/MS or GC-MS/MS
that are complicated, costly, and time consuming rather than
asimpleHPLC-UVmethod.Consideringthepossibleworld-
wide development of counterfeit DEXIFEN, the proposed
method could be useful for the national quality control lab-
oratories in developing countries.
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